Latest News and Press Releases
Want to stay updated on the latest news?
-
BOSTON, June 21, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today...
-
BOSTON, June 14, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today...
-
Company reported $6.8 million in first quarter total revenues, including $5.6 million of Auryxia™ (ferric citrate) net U.S. product sales2016 product sales and cash operating expense guidance...
-
BOSTON, April 14, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to market for people with renal...
-
BOSTON, April 01, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to market for people with renal...
-
Registration trial demonstrated statistically significant differences versus placebo for the primary and all pre-specified secondary endpointsMajority of patients in the ferric citrate group (52...
-
BOSTON, March 01, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to market for people with renal...
-
Fourth quarter Auryxia net U.S. product sales of $4.8 million Keryx provides 2016 Auryxia net U.S. product sales guidance of $31 - $34 millionCompany on track to provide pivotal phase 3 data...
-
BOSTON, Feb. 11, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to market for people with renal...
-
BOSTON, Dec. 22, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal...